MULTIDISCIPLINARY APPROACH TO THE TREATMENT OF LOCALLY AND REGIONALLY ADVANCED NONSMALL CELL LUNG-CANCER - UNIVERSITY-OF-MIAMI EXPERIENCE

被引:10
作者
SRIDHAR, KS
THURER, RJ
MARKOE, AM
CHATOOR, HT
FOUNTZILAS, G
RAUB, WJ
SAVARAJ, N
BEATTIE, EJ
机构
[1] Departments of Medicine, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, lackson Memorial Hospital, Miami, Florida
[2] Departments of Surgery and Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, lackson Memorial Hospital, Miami, Florida
[3] V.A. Medical Center, Miami, Florida
来源
SEMINARS IN SURGICAL ONCOLOGY | 1993年 / 9卷 / 02期
关键词
NONSMALL CELL LUNG CANCER; CHEMOTHERAPY; NEOADJUVANT THERAPY; FED;
D O I
10.1002/ssu.2980090209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An intensive multimodality therapy protocol incorporating neoadjuvant chemotherapy was initiated in July 1985 for patients with either borderline resectable or unresectable non-small cell carcinoma of the lung. Thirty-five patients, 21 men and 14 women were entered till March 1991. The median age was 58 years (27-74). Histology was squamous in 15, adenocarcinoma in 11, large cell in 6, and adenosquamous carcinoma in 3. Initial stages were IIIA in 19 patients, IIIB in 14 and II in 2. All patients tolerated preoperative chemotherapy with 5-FU, etoposide and cisplatin (FED). The response to chemotherapy was complete response in 2 (6%), and partial response in 22 (63%). Thirty-two patients underwent surgery. 26 patients were rendered disease free including two found disease free at surgery. Fifteen underwent pneumonectomy, 14 lobectomy and 3 biopsy only. Interstitial radiation therapy was used in 7 patients. The median survival of all patients was 19 months, those who underwent incomplete surgical resection was 12 months and patients rendered disease free at operation 21 months. Thirteen patients are alive and free of disease, including 6 patients alive longer than 5 years. Only patients who responded to chemotherapy and also had compete resection survived more than 2 years. Aggressive neoadjuvant therapy with FED, followed by resection, brachytherapy, postoperative radiation therapy, and adjuvant chemotherapy can be safely accomplished with encouraging survival in stage III patients.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 18 条
[1]  
Johnson DH, Einhorn LH, Bartolucci A, Et al., Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non‐small cell lung cancer, Ann Intern Med, 113, pp. 33-38, (1990)
[2]  
Hilaris BS, Gomez J, Nori D, Et al., Combined surgery, intraoperative brachytherapy, and post‐operative external RT in stage 111 non‐small cell lung cancer, Cancer, 55, pp. 1226-1231, (1985)
[3]  
Sridhar KS, Varki J, Donnelly E, Et al., Toxicity of FED chemotherapy in non‐small cell lung cancer, Am J Clin Oncol, 10, pp. 499-506, (1987)
[4]  
Sridhar KS, Thurer R, Kim Y, Et al., Multimodality treatment of non‐small cell lung cancer: response to cisplatin, VP‐16, and 5‐FU chemotherapy
[5]  
and to surgery and RT, J Surg Oncol, 38, pp. 193-215, (1988)
[6]  
Sridhar KS, Donnelly E, Combination antiemetics for cisplatin chemotherapy, Cancer, 61, pp. 1508-1517, (1988)
[7]  
Krishan A, Sridhar KS, Sternheim W, Et al., Patterns of anthra‐cycline modulation in human tumor cells, Cytometry, 8, pp. 306-314, (1987)
[8]  
Kaplan EL, Meier P, Nonparametric estimation of incomplete observations, Journal of the American Statistical Association, 53, pp. 457-482, (1958)
[9]  
Minna JD, Pass H, Glatstein E, Ihde DC, Cancer of the lung, Cancer, Principles and Practice of oncology, pp. 591-688, (1989)
[10]  
Strauss GM, Langer MP, Elias AD, Et al., Multi‐modality treatment of stage IIIA non‐small cell lung carcinoma: A critical review of the literature and strategies for future research, J Clin Oncol, 10, pp. 829-839, (1992)